Regular ArticlePotential Cholestatic Activity of Various Therapeutic Agents Assessed by Bile Canalicular Membrane Vesicles Isolated from Rats and Humans
References (37)
- et al.
Molecular pathogenesis of cholestasis
New Engl. J. Med.
(1998) - et al.
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis
Nat. Genet.
(1998) - et al.
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome
Hepatology
(1997) - et al.
Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane
FEBS lett.
(1994) - et al.
Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver
Gastroenterology
(2000) - et al.
ATP-dependent efflux of 2,4-dinitrophenyl-S-glutathione
J. Biol. Chem.
(1995) - et al.
Primary active transport of organic anions on bile canalicular membrane in humans
Am. J. Physiol.
(1999) - et al.
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: Probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites
Drug Metab. Pharmacokin.
(2002) - et al.
A pharmacokinetic analysis program (MULTI) for microcomputer
J. Pharmacobio.-Dyn.
(1981) - et al.
Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
Annu Rev Pharmacol Toxicol.
(1998)
Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments
Drug Metab Dispos.
Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
Pharmacol. Rev.
Chronic administration of cyclosporin A induces a decrease in hepatic excretory function in man
Dig. Dis. Sci.
A proposed mechanism for chlorpromazine jaundice-defective hepatic sulphoxidation combined with rapid hydroxylation
J. Hepatol.
Role of bile salts in colchicine-induced hepatotoxicity. Implication for hepatocellular integrity and function
Toxicology
Colchicine toxicity
Australasian annals of Medicine.
Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat
Mol. Pharmacol.
Cited by (66)
Binding mode analysis of ABCA7 for the prediction of novel Alzheimer's disease therapeutics
2021, Computational and Structural Biotechnology JournalCitation Excerpt :Truly multitarget pan-ABC transporter inhibitors are mostly drugs and drug-like candidates that have been known for a long period of time to interfere with specific ABC transporters [45,69–73] and were broadly evaluated toward several members. These compounds include benzbromarone (6; ABCB1 [74], ABCB11 [75], ABCC1–6 [69,73,76–78], ABCG2 [74]), imatinib (7; ABCA3 [79], ABCB1 [80], ABCB11 [75], ABCC1 [80], ABCC10 [80], ABCG2 [80]), quercetin (8; ABCB1 [76], ABCC1–2 [69,76], ABCC4–5 [81,82], ABCC11 [83], ABCG2 [69], ABCG6 [84]), verapamil (9; ABCA8 [85], ABCB1 [70], ABCB4–5 [86,87], ABCB11 [88], ABCC1 [69], ABCC4 [89], ABCC10 [90], ABCG2 [76]), and verlukast (MK571, 10; ABCA8 [85], ABCB4 [86], ABCB11 [75], ABCC1–5 [69,76,91–93], ABCC10–11 [73,94], ABCG2 [76]), all Fig. 2. Focused pan-ABC transporter inhibitors are high-throughput screening-(HTS)- and/or organic synthesis-derived small-molecules specifically designed to target the well-studied ABC transporters ABCB1, ABCC1, and ABCG2 [38,45].
Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (C@PA)
2021, Computational and Structural Biotechnology JournalCitation Excerpt :Multitargeting is a promising approach to explore under-studied ABC transporters by targeting similar or mutually overlapping binding sites [15,73,74]. Several pharmacological drugs have already been revealed as (weak) pan-ABC transporter inhibitors (=inhibiting several ABC transporters simultaneously), as for example, benzbromarone (1; ABCB1 [75], ABCB11 [20], ABCC1-6 [23,24,58,76,77], and ABCG2 [75]), cyclosporine A (2; ABCA1 [27], ABCB1 [16], ABCB4 [78], ABCB11 [20], ABCC1–2 [23,58], ABCC10 [24], ABCG1–2 [75,79]), glibenclamide (glyburide, 3; ABCA1 [29], ABCB11 [20], ABCC1 [23], ABCC5 [80], ABCC7–9 [81–83], ABCG2 [58]), probenecid (4; ABCA8 [84], ABCC1–6 [23,24,85–87], ABCC10 [88]), verapamil (5; ABCA8 [84], ABCB1 [16], ABCB4–5 [54,78], ABCB11 [89], ABCC1 [23], ABCC4 [90], ABCC10 [88], ABCG2 [58]), or verlukast (MK571, 6; ABCA8 [84], ABCB4 [78], ABCB11 [20], ABCC1–5 [23,58,80,87,91], ABCC10–11 [24,92], ABCG2 [58]). Fig. 1 provides the molecular formulae of the most prominent drug-like pan-ABC transporter inhibitors known until today.
In vitro bile acid-dependent hepatocyte toxicity assay system using human induced pluripotent stem cell-derived hepatocytes: Current status and disadvantages to overcome
2019, Drug Metabolism and PharmacokineticsCitation Excerpt :The BSEP protein was not expressed in SCHiHs (data not shown). On the other hand, the protein expression level of MRP2 in SCHiHs showed a similar trend to that in SCHHs as previously reported [16]. The cell morphology also revealed the presence of canalicular membrane in SCHiHs.
Idiosyncratic Adverse Drug Reactions
2018, Comprehensive Toxicology: Third EditionInhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse
2016, Chemico-Biological Interactions